|Bid||5.27 x 1100|
|Ask||5.32 x 800|
|Day's Range||5.02 - 5.37|
|52 Week Range||4.31 - 13.32|
|Beta (3Y Monthly)||1.18|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 9, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.71|
Biotech stocks continued to languish for a third straight week. Negative broader market sentiment and company-specific weakness weighed down on the sector. Pfenex Inc (NYSE: PFNX ) received FDA approval ...
Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present on Thursday, October 10 at the Ophthalmology Innovation Summit (OIS) at the American Academy of Ophthalmology 2019 Annual Meeting. The presentation will highlight the company’s Phase 3 ocular programs, which target unmet medical needs for dry eye disease, allergic conjunctivitis, and proliferative vitreoretinopathy.
Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra) today announced that it will host an ePoster presentation and discussion of the company’s ALLEVIATE Phase 3 clinical trial of reproxalap in patients with allergic conjunctivitis at the American Academy of Ophthalmology 2019 Annual Meeting, which takes place October 12-15, 2019 at the Moscone Center in San Francisco, California. Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases.
[Editor's Note: This article is updated each week with the latest insider purchasing. Check back regularly to see who's making moves.]An insider is a person who has access to confidential information about a company. And when I'm analyzing a company as a potential long-term investment, I always like to know what the insiders are doing. They have a much better idea of what is happening in the company than most analysts. When there is insider buying after the price of the stock has recently dropped, it could be a bullish signal.Over the years, there have been numerous examples of insiders using this information to profit at the expense of uninformed investors. For example, suppose an insider knows that news is about to be released that will make the stock price go up. They can buy it from a shareholder who doesn't have access to the news at a cheaper price then benefit from the gains.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBecause of these abuses, the SEC has established rules and procedures to prevent this type of activity. When an insider wants to buy or sell their company's stock, they have to file a form with the SEC. This is public information, and it can lead to investment ideas.There are numerous reasons why an insider of a company may need to sell their stock. They may need to raise money for things such as tuition or to buy a home. However, there is only one reason why an insider would buy their company's stock -- they believe that it is undervalued and they will make money. * 7 Stocks to Buy Under $10 These seven stocks have had significant insider buying recently and could be worth a look. Stocks With Insider Buying: Church & Dwight (CHD)Church & Dwight (NYSE:CHD) manufactures and sells household, personal care and specialty products.CHD stock has been under pressure recently. Well-known short seller Ben Axler of Spruce Point Capital Management said that the company engages is "extreme financial engineering, aggressive accounting and material self-enrichment practices." That sounds pretty bad.Matthew Farrell is the president and CEO of Church & Dwight. Apparently he disagrees with this assessment. He must believe that the stock will soon recover because he just made a significant personal investment of $500,000. He bought 7,000 shares at $71.32. Liberty TripAdvisor Holdings (LTRPA)Liberty TripAdvisor Holdings (NASDAQ:LTRPA) engages in online travel research and online commerce business.Over the past year, the price of LTRPA has fallen dramatically. Last November it traded as high as $20. Now it is trading below $10. Wall Street is neutral on the company. Only two firms follow it, and they each have hold ratings on it. * 30 Marijuana Stocks to Buy as the Future Turns Green Gregory Maffei has been an officer of Liberty for five years. He is the chairman, president and CEO of the company. He must feel that the stock is a great value at current levels, because he just invested $160,000 when he paid $10.38 a share for over 15,000 shares. Pacific Mercantile Bancorp (PMBC)Pacific Mercantile Bancorp (NASDAQ:PMBC) operates as a holding company that provides a range of commercial banking and services to small- and medium-sized businesses.After making a significant drop in price from last September through December, PMBC stock has been volatile but it has basically traded sideways.The Board of Directors just announced that they have appointed Brad Dinsmore as the president and CEO of the company. From 2011 to 2017, Dinsmore was executive vice president of SunTrust Banks.He must have a lot of confidence that he will be able to take actions that will cause the price of the stock to rise. He recently paid $7.98 for 28,000 shares. This is an investment of almost $225,000. Pennsylvania Real Estate Investment Trust (PEI)Pennsylvania Real Estate Investment Trust (NYSE:PEI) is a publicly traded REIT that owns and manages quality properties in compelling markets.PEI stock has sold off significantly over the past year. Last August it was trading around $11 a share. It is currently trading around the $5.50 level.Wall Street does not like this stock. Seven firms follow it. The average rating in underweight and the average price target is $5.25, which is below where it is currently trading. * 7 Triple-'F' Rated Stocks to Leave on the Shelf Leonard Korman is a director of PEI. Apparently he believes that the stock will turn around because he just paid $5.29 for 30,000 shares. In August he also bought 30,000 shares as well. His total investment was about $300,000. There was also buying by other insiders as well. Aldeyra Therapeutics (ALDX)Aldeyra Therapeutics (NASDAQ:ALDX) is a biotechnology company that develops and commercializes medicines for immune-mediated ocular and systemic diseases.ALDX stock has lost over 50% of its value in the past year. This isn't surprising because the company loses a lot of money. Last quarter it reported losses of $13 million and in the prior quarter the loss was more than $15 million.Todd Brady, the president and CEO of Aldeyra, invested roughly $85,000 into the company on Sept. 18, buying 14.288 shares at $5.91 per share. In addition, on Sept. 9 and Sept. 10 he paid an average of $5.14 for 20,000 shares. This was a $100,000 investment. Sarepta Therapeutics (SRPT)Sarepta Therapeutics (NASDAQ:SRPT) focuses of the discovery and development of medicines for rare diseases.Over the past two months, the price of SRPT stock has lost 50% of its value. It dropped from levels around $160 to current levels around $80.This is primarily due to the fact that the company received some disappointing news from the FDA. First, one of their drugs that is in a clinical trial caused serious side effects. Second, another drug has to be delayed beyond when it was supposed to hit the market. * 8 Dividend Stocks to Buy for a Recession Richard Barry is a director of the company. He must believe that this selling has created a buying opportunity. He just invested almost $290,000 when he bought 3,309 shares at $87.49. Lexicon Pharmaceuticals (LXRX)Lexicon Pharmaceuticals (NASDAQ:LXRX) is a biopharmaceutical company that develops and sells pharmaceutical products.The price of LXRX stock had been trending lower for almost a year. Then at the end of July it reported that its partnership with Sanofi (NASDAQ:SNY) had terminated the partnership and plunged from $6 to $2.The insiders of the company must believe that this selling was overdone because they have been making significant purchases of the stock.Lonnel Coats is the president and CEO of Lexicon Pharmaceuticals. He invested over $300,000 in the stock when he acquired 100,000 shares for an average price of around $3.11. Raymond Debbane is a director of the company. He just made an investment of about $700,000 when he bought about 290,000 shares. There have been purchases by other insiders as well.At the time of this writing Mark Putrino did not hold any positions in the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy Under $10 * 30 Marijuana Stocks to Buy as the Future Turns Green * 7 Consumer Stocks Ready to Rally Hard The post 7 Stocks the Insiders Are Buying on Sale appeared first on InvestorPlace.
Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the 2019 Cantor Global Healthcare Conference. Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome.
Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ADX-2191 for the prevention of proliferative vitreoretinopathy (PVR). “Fast track designation is an important milestone for our retinal disease platform, and promising news for PVR patients,” said Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra. PVR, a rare inflammatory disorder of the retina that leads to severe retinal scarring and blindness, occurs most commonly following retinal detachment repair surgery or ocular injury.
President and CEO of Aldeyra Therapeutics Inc (30-Year Financial, Insider Trades) Todd C Brady (insider trades) bought 20,000 shares of ALDX on 09/10/2019 at an average price of $5.14 a share. Continue reading...
A look at the shareholders of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) can tell us which group is most powerful...
Billionaire hedge fund managers such as David Abrams, Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the […]
Shares of Aldeyra Therapeutics Inc (NASDAQ: ALDX ), a thinly traded micro-cap biotech, plummeted Tuesday morning. What Happened Aldeyra, which focuses on therapies for immune-mediated diseases, reported ...
“The results of the SOLACE Trial confirm the potential of reproxalap to treat ocular inflammation, and further validate the novel mechanism of action of reproxalap, which demonstrated highly statistically significant immune-modulating activity in the Phase 3 ALLEVIATE Trial and Phase 2b Dry Eye Disease trial,” stated Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra. Reproxalap ophthalmic solution, in various concentrations, has now been administered to over 800 patients in nine clinical trials for ocular inflammation.
Aldeyra Therapeutics, Inc. , a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced it will hold a webcast and conference call on Tuesday, June 25, 2019 at 8:00 a.m.
LEXINGTON, Mass. , May 30, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve ...
- Reported Positive Results from Phase 3 ALLEVIATE Trial in Allergic Conjunctivitis - Initiated Adaptive Phase 3 RENEW Trial in Dry Eye Disease - Last Patient Dosed in Phase 3 SOLACE Trial in Noninfectious ...
LEXINGTON, Mass. , May 2, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve ...
LEXINGTON, Mass., April 30, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that the last patient has completed dosing in the SOLACE Phase 3 clinical trial of topical ocular reproxalap in patients with noninfectious anterior uveitis. "We look forward to announcing the results of the SOLACE trial, our second Phase 3 clinical trial to complete this year," stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. "Noninfectious anterior uveitis is a rare but severe inflammatory ocular disease characterized by pain, photophobia, and, in some cases, vision loss.
Reproxalap is a novel immune-modulating RASP (Reactive Aldehyde Species) inhibitor in late-stage development for the treatment of dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson Syndrome. Results from a Phase 2b clinical trial completed in 2018 demonstrated that reproxalap was statistically superior to vehicle across multiple dry eye disease symptoms and signs. The RENEW adaptive Phase 3 clinical trial of topical ocular reproxalap for the treatment of dry eye disease initiated on April 1, 2019.
LEXINGTON, Mass., April 2, 2019 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced enrollment of the first patient into the RENEW Phase 3 clinical trial of topical ocular reproxalap for the treatment of dry eye disease. The RENEW Trial is a two-part, multi-center, randomized, double-masked, parallel-group, vehicle-controlled, adaptive Phase 3 clinical trial evaluating the efficacy of reproxalap ophthalmic solution (0.25%) vs. vehicle in 400 patients with moderate-to-severe dry eye disease. Results from the first part of the trial will confirm the dosing regimen and sample size for the second part. The co-primary endpoints of the trial will be ocular dryness and fluorescein nasal region ocular staining in pre-specified moderate to severe patient subsets analyzed over twelve weeks of therapy using Mixed effects Model Repeated Measures (MMRM).